Alpha-1 antitrypsin deficiency (AATD)
Alpha-1 antitrypsin deficiency (AATD) is a rare genetic condition which can cause lung disease in adults with symptoms similar to chronic obstructive pulmonary diseases. AATD is largely underdiagnosed, with an estimated prevalence of 100,000 individuals with AATD in the United States (US); however, fewer than 10,000 individuals are diagnosed with the disorder. Previously, AATD was thought to affect only White individuals of European descent. Recent studies have shown that people of different races and ethnicities have genotypes consistent with those with moderate-to-severe AATD-related lung disease.
We developed a prediction model to identify symptomatic patients of different races and ethnicities with likely risk of AATD using claims data from a large US database.
This poster was developed together with Takeda and presented at the American Thoracic Society International Conference 2024.
Tech Tour Growth Health is one of Europe's most established gatherings at the intersection of…
Volv Global is pleased to be participating in the Life Sciences Innovation & Investment Corridor…
The idea that an AI system could detect a disease that appears nowhere in a…
The ISPOR International Annual Conference 2026 brings together global leaders in health economics and outcomes…
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Inflammatory Bowel Disease (IBD) management has…
Introduction Advocacy plays a critical role in accelerating progress in rare diseases. As technology advances,…